Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Capecitabine for Breast Cancer.
Toi M, Masuda N, Ohashi Y. Toi M, et al. Among authors: ohashi y. N Engl J Med. 2017 Aug 24;377(8):791-2. doi: 10.1056/NEJMc1708487. N Engl J Med. 2017. PMID: 28834474 No abstract available.
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Kimura M, et al. Among authors: ohashi y. Breast Cancer. 2010 Jul;17(3):190-8. doi: 10.1007/s12282-009-0132-x. Epub 2009 Jul 3. Breast Cancer. 2010. PMID: 19575284 Clinical Trial.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Tominaga T, et al. Among authors: ohashi y. J Clin Oncol. 2003 Mar 15;21(6):991-8. doi: 10.1200/JCO.2003.06.014. J Clin Oncol. 2003. PMID: 12637462 Clinical Trial.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ohashi y. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Among authors: ohashi y. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.
2,167 results